The DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index.
Multi-functional nanocarriers to overcome tumor drug resistance
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting HIF-1 for cancer therapy
Semenza, G. L. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1187 · Cited by 6,717
Multidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536
Hypoxia — a key regulatory factor in tumour growth
Harris, A. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc704 · Cited by 5,177
Targeting multidrug resistance in cancer
Szakács, G., Paterson, J. K., Ludwig, J. A., Booth-Genthe, C., & Gottesman, M. M. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1984 · Cited by 3,609
Long-Circulating and Target-Specific Nanoparticles: Theory to Practice
Moghimi, S. M., Hunter, A. C., & Murray, J. C. (2001) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01494-7 · Cited by 3,515
Stewart, B. W., & Kleihues, P. (2003) · Cited by 2,386
Drug Resistance and the Solid Tumor Microenvironment
Tredan, O., Galmarini, C. M., Patel, K., & Tannock, I. F. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm135 · Cited by 2,116 · cited 6×
“Although tumors are highly heterogeneous, the anatomy of a tumor more closely resembles a haphazard pattern than a coreshell structure [20].”
BackgroundInfluentialNanomedicine: current status and future prospects
Moghimi, S. M., Hunter, A. C., & Murray, J. C. (2005) · The FASEB Journal · doi:10.1096/fj.04-2747rev · Cited by 2,029
(1996) · PubMed · Cited by 1,188
Semenza, G. L., Nejfelt, M. K., Chi, S. M., & Antonarakis, S. E. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.13.5680 · Cited by 990
Cited by
Nanotechnology for Multimodal Synergistic Cancer Therapy
Fan, W., Yung, B., Huang, P., & Chen, X. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00258 · Cited by 1,791
Carbon nanotubes: properties, synthesis, purification, and medical applications
Eatemadi, A., Daraee, H., Karimkhanloo, H., Kouhi, M., Zarghami, N., Akbarzadeh, A., Abasi, M., Hanifehpour, Y., & Joo, S. W. (2014) · Nanoscale Research Letters · doi:10.1186/1556-276x-9-393 · Cited by 1,239
Effect of Zeta Potential on the Properties of Nano-Drug Delivery Systems - A Review (Part 1)
Honary, S., & Zahir, F. (2013) · Tropical Journal of Pharmaceutical Research · doi:10.4314/tjpr.v12i2.19 · Cited by 1,138
Meng, H., Liong, M., Xia, T., Li, Z., Ji, Z., Zink, J. I., & Nel, A. E. (2010) · ACS Nano · doi:10.1021/nn100690m · Cited by 902
Current Trends in The Use of Liposomes for Tumor Targeting
Deshpande, P. P., Biswas, S., & Torchilin, V. P. (2013) · Nanomedicine · doi:10.2217/nnm.13.118 · Cited by 657
Croissant, J. G., Fatieiev, Y., Almalik, A., & Khashab, N. M. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201700831 · Cited by 594
Meng, H., Mai, W. X., Zhang, H., Xue, M., Xia, T., Lin, S., Wang, X., Zhao, Y., Ji, Z., Zink, J. I., et al. (2013) · ACS Nano · doi:10.1021/nn3044066 · Cited by 575
Multifunctional nanoparticle-mediated combining therapy for human diseases
Li, X., Peng, X., Zoulikha, M., Boafo, G. F., Magar, K. T., Ju, Y., & He, W. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01668-1 · Cited by 521
Deng, X., Cao, M., Zhang, J., Hu, K., Yin, Z., Zhou, Z., Xiao, X., Yang, Y., Sheng, W., Wu, Y., et al. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2014.02.006 · Cited by 511
Ganta, S., & Amiji, M. (2009) · Molecular Pharmaceutics · doi:10.1021/mp800240j · Cited by 490
Self-citationExtracellularly Activated Nanocarriers: A New Paradigm of Tumor Targeted Drug Delivery
Gullotti, E., & Yeo, Y. (2009) · Molecular Pharmaceutics · doi:10.1021/mp900090z · Cited by 473
Multifunctional polymeric micelles for delivery of drugs and siRNA
Jhaveri, A. M., & Torchilin, V. P. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00077 · Cited by 466
Inorganic Nanoparticles in Cancer Therapy
Bhattacharyya, S., Kudgus, R. A., Bhattacharya, R., & Mukherjee, P. (2011) · Pharmaceutical Research · doi:10.1007/s11095-010-0318-0 · Cited by 395
Gandhi, N. S., Tekade, R. K., & Chougule, M. B. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.09.001 · Cited by 394
Duan, X., Xiao, J., Yin, Q., Zhang, Z., Yu, H., Mao, S., & Li, Y. (2013) · ACS Nano · doi:10.1021/nn4010796 · Cited by 379
Role of integrated cancer nanomedicine in overcoming drug resistance
Iyer, A. K., Singh, A., Ganta, S., & Amiji, M. M. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.07.012 · Cited by 343
Self-citationCarbon nanotubes in cancer diagnosis and therapy
Ji, S.-R., Liu, C., Zhang, B., Yang, F., Xu, J., Long, J., Jin, C., Fu, D.-L., Ni, Q.-X., & Yu, X.-J. (2010) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2010.02.004 · Cited by 338
Nanopreparations to overcome multidrug resistance in cancer
Patel, N. R., Pattni, B. S., Abouzeid, A. H., & Torchilin, V. P. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.08.004 · Cited by 333
Triple-Negative Breast Cancer: A Review of Conventional and Advanced Therapeutic Strategies
Medina, M. A., Oza, G., Sharma, A., Arriaga, L. G., Hernández Hernández, J. M., Rotello, V. M., & Ramirez, J. T. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17062078 · Cited by 333
Deng, X., Liang, S., Cai, X., Huang, S., Cheng, Z., Shi, Y., Pang, M., Ma, P., & Lin, J. (2019) · Nano Letters · doi:10.1021/acs.nanolett.9b01716 · Cited by 319
Convection-enhanced delivery of nanocarriers for the treatment of brain tumors
Allard, E., Passirani, C., & Benoit, J.-P. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2009.01.003 · Cited by 294
Doxorubicin loaded iron oxide nanoparticles overcome multidrug resistance in cancer in vitro
Kievit, F. M., Wang, F. Y., Fang, C., Mok, H., Wang, K., Silber, J. R., Ellenbogen, R. G., & Zhang, M. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.01.024 · Cited by 289
Targeting carbon nanotubes against cancer
Fabbro, C., Ali-Boucetta, H., Ros, T. D., Kostarelos, K., Bianco, A., & Prato, M. (2012) · Chemical Communications · doi:10.1039/c2cc17995d · Cited by 281
Best Practices in Cancer Nanotechnology: Perspective from NCI Nanotechnology Alliance
Zamboni, W. C., Torchilin, V., Patri, A. K., Hrkach, J., Stern, S., Lee, R., Nel, A., Panaro, N. J., & Grodzinski, P. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2938 · Cited by 275
Wang, Y.-C., Wang, F., Sun, T.-M., & Wang, J. (2011) · Bioconjugate Chemistry · doi:10.1021/bc200139n · Cited by 268
Exploiting nanotechnology to overcome tumor drug resistance: Challenges and opportunities
Kirtane, A. R., Kalscheuer, S. M., & Panyam, J. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.09.001 · Cited by 258
Prakash, S., Malhotra, M., Shao, W., Tomaro-Duchesneau, C., & Abbasi, S. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.06.013 · Cited by 256
Tang, R., Ji, W., Panus, D., Palumbo, R. N., & Wang, C. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.12.005 · Cited by 202
Nanoformulations for combination or cascade anticancer therapy
Miao, L., Guo, S., Lin, C. M., Liu, Q., & Huang, L. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.06.003 · Cited by 178
“Several other ABC transporters that are associated with MDR include multi-drug resistance protein 1 (MRP-1, ABCC1), breast cancer resistance protein (BCRP, ABCG2), the mitoxantrone resistance protein (MXR/BCRP, ABCG2) and ABCB4 (MDR3) [1, 35].”
BackgroundRole of cellular uptake in the reversal of multidrug resistance by PEG-b-PLA polymeric micelles
Xiao, L., Xiong, X., Sun, X., Zhu, Y., Yang, H., Chen, H., Gan, L., Xu, H., & Yang, X. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.03.071 · Cited by 169
Kankala, R. K., Liu, C.-G., Yang, D.-Y., Wang, S.-B., & Chen, A.-Z. (2020) · Chemical Engineering Journal · doi:10.1016/j.cej.2019.123138 · Cited by 157
Nanocosmetics and Nanomedicines
(2011) · doi:10.1007/978-3-642-19792-5 · Cited by 116
Toxicity of Carbon Nanotubes as Anti-Tumor Drug Carriers
Yan, H., Xue, Z., Xie, J., Dong, Y., Ma, Z., Sun, X., Kebebe Borga, D., Liu, Z., & Li, J. (2019) · International Journal of Nanomedicine · doi:10.2147/ijn.s220087 · Cited by 113
Riganti, C., Voena, C., Kopecka, J., Corsetto, P. A., Montorfano, G., Enrico, E., Costamagna, C., Rizzo, A. M., Ghigo, D., & Bosia, A. (2011) · Molecular Pharmaceutics · doi:10.1021/mp2001389 · Cited by 86
Pinzón‐Daza, M., Garzón, R., Couraud, P., Romero, I., Weksler, B., Ghigo, D., Bosia, A., & Riganti, C. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.02103.x · Cited by 84
Callari, M., De Souza, P. L., Rawal, A., & Stenzel, M. H. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201701471 · Cited by 68
Nanodelivery Systems for Nucleic Acid Therapeutics in Drug Resistant Tumors
Iyer, A. K., Duan, Z., & Amiji, M. M. (2014) · Molecular Pharmaceutics · doi:10.1021/mp500024p · Cited by 55
Self-citationLi, Y., Li, R., Liu, Q., Li, W., Zhang, T., Zou, M., Li, H., Wu, T., Cheng, S., Su, Z., et al. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b00712 · Cited by 16
Metadata
- Authors
- Jabr-Milane, L. S., van Vlerken, L. E., Yadav, S., & Amiji, M. M.
- Venue
- Cancer Treatment Reviews
- Publisher
- Elsevier BV
- Published
- 2008-11
- Volume
- 34
- Issue
- 7
- Pages
- 592-602
- ISSN
- 0305-7372 (ISSN-L)
- OpenAlex
- W2152504641
- Cited by
- 407
- References
- 74
- FWCI
- 9.04
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.